C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.[1] Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.[2] It is selectively downregulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.[3]

2304-81-6

C36H71NO3

565.95

C18 Ceramide (d18:1/18:0);C18 Ceramide (d18:1/18:0)

DMF:0.15 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years